Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-43.37% $0.270
America/New_York / 22 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 34.17 mill |
EPS: | -0.450 |
P/E: | -0.600 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 126.75 mill |
Avg Daily Volume: | 0.447 mill |
RATING 2024-04-22 |
---|
B- |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Strong Sell | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.600 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.10x |
Company: PE -0.600 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0801 (-129.71%) $-0.350 |
Date: 2024-04-23 |
Expected Trading Range (DAY) |
---|
$ 0.197 - 0.343 ( +/- 27.08%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-11-03 | Paula Molina Rene | Buy | 0 | |
2023-10-02 | Powchik Peter | Buy | 159 744 | Stock option (right to buy) |
2023-10-01 | Ray Sumita | Buy | 0 | |
2023-09-06 | Prime Movers Lab Fund I Lp | Sell | 5 308 | Class A Common Stock |
2023-09-07 | Prime Movers Lab Fund I Lp | Sell | 20 312 | Class A Common Stock |
INSIDER POWER |
---|
49.32 |
Last 91 transactions |
Buy: 5 925 518 | Sell: 2 685 509 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.270 (-43.37% ) |
Volume | 5.72 mill |
Avg. Vol. | 0.447 mill |
% of Avg. Vol | 1 278.21 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; anti-PCSK9 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Dallas, Texas.